https://www.optimumcomms.com/wp-content/uploads/2026/04/asgard-logo-for-website.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-28 08:33:582026-04-28 08:33:58Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy
https://www.optimumcomms.com/wp-content/uploads/2026/04/asgard-logo-for-website.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-28 08:33:582026-04-28 08:33:58Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-28 07:15:062026-04-28 08:43:57Poolbeg Pharma plc – Results for the year ended 31 December 2025
https://www.optimumcomms.com/wp-content/uploads/2026/04/asgard-logo-for-website.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-24 12:37:372026-04-24 12:37:37Oncoinvent ASA: Annual Report for 2025
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-23 06:29:372026-04-23 06:32:52Hansa Biopharma Report First Quarter 2026 Financial Results
https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-21 15:55:302026-04-21 15:58:40Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-21 09:04:182026-04-21 09:04:18Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization
https://www.optimumcomms.com/wp-content/uploads/2026/04/asgard-logo-for-website.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-20 08:30:412026-04-20 08:30:41Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
https://www.optimumcomms.com/wp-content/uploads/2023/09/WiLD_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-17 08:34:562026-04-17 08:34:56New Nordic white paper reveals systemic barriers preventing women from reaching leadership roles
https://www.optimumcomms.com/wp-content/uploads/2024/11/Freya_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-16 08:38:262026-04-16 08:39:48Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-16 08:10:292026-04-16 08:10:29STORM Therapeutics secures $56 Million Series C financing and doses first patient in Phase 2 sarcoma trial of STC‑15
https://www.optimumcomms.com/wp-content/uploads/2026/04/Minervax_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-15 08:45:512026-04-15 08:45:51MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-15 08:34:122026-04-15 08:34:12Poolbeg Pharma plc – MHRA grants Clinical Trial Authorisation for the TOPICAL trial and independent research confirms significant commercial opportunity for POLB 001
https://www.optimumcomms.com/wp-content/uploads/2024/03/Asgard_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-14 08:43:072026-04-14 08:43:07Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development
https://www.optimumcomms.com/wp-content/uploads/2026/02/Laigo-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-14 08:33:572026-04-14 08:34:19Laigo Bio strengthens team with Chief Scientific Officer and Scientific Advisory Board appointments
https://www.optimumcomms.com/wp-content/uploads/2026/03/Mestag_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-14 08:33:552026-04-14 08:33:55Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2026/01/Kainova_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-09 08:46:572026-04-09 08:46:57Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in EuropeWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
